NCT06503276View on ClinicalTrials.gov

The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2028

Conditions
Extranodal Marginal Zone B-cell Lymphoma
Interventions
DRUG

Orelabrutinib

Orelabrutinib PO will be administered as per the schedule specified in the respective arm

RADIATION

Ultra-low dose radiotherapy

2 Gy radiotherapy will be administerd twice in the first cycle

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER